Extended-release naltrexone for people with alcohol use disorder on therapeutic anticoagulation: A case series.

Autor: Ciraldo K; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Miami, Miami, Florida, USA.; Department of Family Medicine and Community Health, University of Miami, Miami, Florida, USA., Seraydarian M; San Francisco General Hospital, San Francisco, California, USA., Gasper J; Department of Family and Community Medicine, San Francisco General Hospital, San Francisco, California, USA., DeFries T; San Francisco General Hospital, San Francisco, California, USA.; Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Martin M; San Francisco General Hospital, San Francisco, California, USA.; Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
Jazyk: angličtina
Zdroj: Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2022 Dec; Vol. 47 (12), pp. 2393-2396. Date of Electronic Publication: 2022 Dec 13.
DOI: 10.1111/jcpt.13800
Abstrakt: What Is Known and Objective: Individuals with medication adherence challenges or a preference for long-acting medications may benefit from extended-release naltrexone (XR-NTX) for treatment of alcohol use disorder (AUD). Individuals on therapeutic anticoagulation were excluded from XR-NTX studies and its safety in this population has not been reported.
Case Summary: We conducted structured retrospective chart review of six individuals who received XR-NTX for AUD while on therapeutic anticoagulation between November 2019 and Deccember 2020. We found no documented complications among six individuals who received up to 11 doses of XR-NTX while on therapeutic anticoagulation.
What Is New and Conclusion: XR-NTX may be safely tolerated by patients on therapeutic anticoagulation. We need larger studies evaluating XR-NTX administration in patients on therapeutic anticoagulation and those with coagulopathies, including individuals with alcohol-related liver disease, to better quantify risks and benefits for shared decision-making.
(© 2022 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje